 | Up a level |
Viale, G.; Giobbie-Hurder, A.; Gusterson, B. A.; Maiorano, E.; Mastropasqua, M. G.; Sonzogni, A.; Mallon, E.; Colleoni, M.; Castiglione-Gertsch, M.; Regan, M. M.; Price, K. N.; Brown, R. W.; Golouh, R.; Crivellari, D.; Karlsson, P.; Öhlschlegel, C.; Gelber, R. D.; Goldhirsch, A.; Coates, A. S. (2009). Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Annals of oncology, 21(2), pp. 245-254. Oxford University Press 10.1093/annonc/mdp317
Regan, M. M.; Pagani, O.; Walley, B.; Torrisi, R.; Perez, E. A.; Francis, P.; Fleming, G. F.; Price, K. N.; Thürlimann, B.; Maibach, R.; Castiglione-Gertsch, M.; Coates, A. S.; Goldhirsch, A.; Gelber, R. D. (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Annals of oncology, 19(7), pp. 1231-1241. Oxford University Press 10.1093/annonc/mdn037
Waeber, M.; Castiglione-Gertsch, M.; Dietrich, D.; Thürlimann, B.; Goldhirsch, A.; Brunner, K. W.; Borner, M. M. (2003). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Annals of oncology, 14(8), pp. 1215-1221. Oxford University Press 10.1093/annonc/mdg347
Aebi, S.; Castiglione-Gertsch, M. (2001). High-dose chemotherapy for ovarian cancer: Are we ready to go? Annals of oncology, 12(5), pp. 583-584. Oxford University Press 10.1023/A:1011134312452
Goldhirsch, A.; Coates, A. S.; Castiglione-Gertsch, M.; Gelber, R. D. (1998). New treatments for breast cancer: Breakthroughs for patient care or just steps in the right direction? Annals of oncology, 9(9), pp. 973-976. Oxford University Press 10.1023/A:1008436810268
Thürlimann, B.; Beretta, K.; Bacchi, M.; Castiglione-Gertsch, M.; Goldhirsch, A.; Jungi, W. F.; Cavalli, F.; Senn, H.-J.; Fey, M.; Löhnert, T. (1996). First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Annals of oncology, 7(5), pp. 471-479. Oxford University Press 10.1093/oxfordjournals.annonc.a010635
